triple negative breast cancer

[Acta Pharmacologica Sinica] Researchers investigated whether and how inhibition of autophagy/mitophagy by cepharanthine affected the efficacy of chemotherapeutic agent epirubicin in TNBC cells in vitro and in vivo.

[Clinical Cancer Research] Scientists performed transcriptional profiling of tumors from a Phase II clinical trial of platinum chemotherapy for advanced TNBC, revealing a gene expression signature that identified de novo chemorefractory tumors.

[Scientific Reports] Following conjugation to β-lactam-derivatized monomethyl auristatin F, tropomyosin receptor kinase B cell surface protein-targeting dual variable domain-antibody–drug conjugates showed potency against multiple breast cancer cell lines, including TNBC cell lines.

[Biochimica et Biophysica Acta-Reviews On Cancer] Investigators review the current progress targeting different immune checkpoints in several-lines treatment for TNBC, including programmed death-1/programmed death ligand-1 inhibitors, cytotoxic T-lymphocyte associated antigen-4 inhibitor, and other novel immunotherapeutic approaches.

[Nature Communications] Investigators found that tumor endothelial marker 8 (TEM8) was abundantly expressed in triple-negative breast cancer and served as a marker for vasculogenic mimicry-forming breast tumor-initiating cells.

[Molecular Therapy] The primary TNBC tumor-derived C-X-C motif chemokines 1/2/8 stimulated lung resident fibroblasts to produce C-C motif chemokines 2/7, which in turn activated cholesterol synthesis in lung-colonizing TNBC cells and induced angiogenesis at lung metastatic sites.